AstraZeneca: FDA panel backs pancreatic cancer drug
(CercleFinance.com) - An FDA advisory committee has recommended that the agency approve AstraZeneca and Merck's drug Lynparza for the treatment of metastatic pancreatic cancer.
The US Food and Drug Administration's oncologic drugs advisory committee has voted 7 to 5 to recommend Lynparza as a first-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas, whose disease has not progressed following chemotherapy, the drugmakers said.
Patients with advanced pancreatic cancer have faced poor outcomes historically, due to the aggressive nature of the disease and limited treatment.
However, in a phase III trial, Lynparza nearly doubled the time patients with metastatic pancreatic cancer lived without disease progression, or death.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US Food and Drug Administration's oncologic drugs advisory committee has voted 7 to 5 to recommend Lynparza as a first-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas, whose disease has not progressed following chemotherapy, the drugmakers said.
Patients with advanced pancreatic cancer have faced poor outcomes historically, due to the aggressive nature of the disease and limited treatment.
However, in a phase III trial, Lynparza nearly doubled the time patients with metastatic pancreatic cancer lived without disease progression, or death.
Copyright (c) 2019 CercleFinance.com. All rights reserved.